Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension
Por:
Kimball, AB, Luger, T, Gottlieb, A, Puig, L, Kaufmann, R, Burge, R, Lin, CY, Yosipovitch, G
Publicada:
1 ene 2018
Resumen:
Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance therapy (80mg ixekizumab every 4 weeks [IXEQ4W]) on itch severity, using the Itch Numeric Rating Scale, in psoriasis patients who received ixekizumab, placebo, or etanercept for 12 weeks in the Phase III UNCOVER-3 trial. After 12 weeks, patients either continued or switched to IXEQ4W. Mean improvements in itch severity achieved with 12 weeks of ixekizumab (-4.7 to -5.1) were maintained through 60 weeks with IXEQ4W (-4.9 to -5.0). Patients who initially received placebo or etanercept experienced rapid itch severity improvements after switching to ixekizumab at Week 12 (Week 12, placebo: -0.6; etanercept: -3.8; Week 60, placebo/ IXEQ4W: -4.9; etanercept/ IXEQ4W: -4.7). Ixekizumab maintenance therapy sustained improvements in itch severity through 60 weeks.
Filiaciones:
Kimball, AB:
Beth Israel Deaconess Med Ctr, 375 Longwood Ave, Boston, MA 02215 USA
Harvard Med Sch, 375 Longwood Ave, Boston, MA 02215 USA
Luger, T:
Univ Munster, Dept Dermatol, Munster, Germany
Gottlieb, A:
New York Med Coll, Dept Dermatol, Valhalla, NY 10595 USA
Puig, L:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Kaufmann, R:
Goethe Univ, Frankfurt, Germany
Burge, R:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Univ Cincinnati, Winkle Coll Pharm, Cincinnati, OH USA
Lin, CY:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Yosipovitch, G:
Univ Miami, Miller Sch Med, Dept Dermatol, Miami, FL 33136 USA
Gold
|